Cleo Diagnostics (ASX:COV) is attempting to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in nonmalignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide | Investor presentation: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02774453-3A636747
EMH
0.38
76.7%
C7A
0.002
-50%
DTM
0.055
66.7%
BOC
0.6
-47.8%
SRL
6.62
56.5%
TR2
0.395
-35.2%
CLE
0.065
54.8%
1TT
0.002
-33.3%
CBE
0.15
53.1%
BLZ
0.002
-33.3%
BIT
0.003
50%
LNU
0.002
-33.3%
EXR
0.063
50%
M2M
0.012
-29.4%
M2R
0.003
50%
MGU
0.005
-28.6%
TGN
0.225
50%
EZZ
1.7
-28.1%
MTM
1.02
48.9%
VMM
0.98
-26.9%
TNC
0.605
47.6%
PGY
0.003
-25%
AUR
0.023
43.8%
KOB
0.055
-23.6%
SRJ
0.017
41.7%
FMR
0.26
-21.2%
ZNC
0.115
40.2%
BOA
0.027
-20.6%
AEU
0.335
39.6%
AUG
0.035
-20.5%
EQR
0.064
39.1%
OEL
0.004
-20%
SKM
0.285
39%
VEN
0.004
-20%
DGR
0.025
38.9%
OCT
0.037
-19.6%
HIQ
0.025
38.9%
L1M
0.031
-18.4%
PTX
0.074
37%
DKM
0.14
-17.6%
